Category: piperazines

Martinez-Espinosa, Juan Carlos; Rodriguez-Villalon, Osvaldo; Cordova-Fraga, Teodoro; Perez-Careta, Eduardo; Guzman-Sepulveda, Jose Rafael; Madrid-Molina, Laura; Guzman-Cabrera, Rafael published an article in 2020, the title of the article was Quantitative pharmaceutical analysis based on the PCA of Raman spectra.Product Details of 86393-32-0 And the article contains the following content:

In the present work we examine the distribution of ciprofloxacin drug as an active ingredient in tablets samples from eight different laboratories Addnl., control samples with different concentration were prepared for calibration. Raman spectra were recorded from all samples, including controls, and a principal component anal. (PCA) was implemented on them. The results of the PCA on control samples show that a clear discrimination among the different samples can be achieved and, more importantly, that the principal component of the Raman spectra has a well-defined, linear relation with the concentration of ciprofloxacin. Such a strong, statistically significant linear correlation obtained for the control samples constitutes our calibration for the quant. anal. of com. pharmaceutical compounds The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to principal component analysis quant pharmaceutical raman spectrum, Organic Analytical Chemistry: Determinations and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 11, 2006, Dillen, Kathleen; Vandervoort, Jo; Van den Mooter, Guy; Ludwig, Annick published an article.Electric Literature of 86393-32-0 The title of the article was Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. And the article contained the following:

The objective of present study was to prepare pos. charged ciprofloxacin-loaded nanoparticles providing a controlled release formulation. The particles were prepared by water-in-oil-in-water (w/o/w) emulsification and solvent evaporation, followed by high-pressure homogenization. Two non-biodegradable pos. charged polymers, Eudragit RS100 and RL100, and the biodegradable polymer poly(lactic-co-glycolic acid) or PLGA were used alone or in combination, with varying ratios. The formulations were evaluated in terms of particle size and zeta potential. Differential scanning calorimetry measurements were carried out on the nanoparticles and on the pure polymers Eudragit and PLGA. Drug loading and release properties of the nanoparticles were examined The antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus was determined During solvent evaporation, the size and zeta potential of the nanoparticles did not change significantly. The mean diameter was dependent on the presence of Eudragit and on the viscosity of the organic phase. The zeta potential of all Eudragit containing nanoparticles was pos. in ultrapure water (around +21/+25 mV). No burst effect but a prolonged drug release was observed from all formulations. The particles’ activity against P. aeruginosa and S. aureus was comparable with an equally concentrated ciprofloxacin solution The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Electric Literature of 86393-32-0

The Article related to ciprofloxacin eudragit polylactide polyglycolide nanoparticle, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 3, 2008, Tornero Montano, Jose Ruben; Quintana Hau, Juan De Dios; Baiza Duran, Leopoldo Martin; Rodriguez Franco, Norma Patricia; Gonzalez, Jaime R.; Jimenez Bayardo, Arturo published a patent.Formula: C17H21ClFN3O4 The title of the patent was An ophthalmic formulation in suspension of loteprednol etabonate and ciprofloxacin hydrochloride. And the patent contained the following:

The invention concerns a topically applied ophthalmic formulation in suspension which contains loteprednol etabonate and ciprofloxacin hydrochloride. Moreover, said formulation contains a polymer as a thickening agent which is derived from the acrylic acid known generically as Carbopol, a nonionic surfactant, an ionic tonicity agent and a nonionic tonicity agent, which are physico-chem. compatible, stable and appropriately dissolved in the suspension. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to loteprednol etabonate ciprofloxacin ophthalmic formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 11, 2003, Sherman, Bernard Charles published a patent.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Tablets comprising ciprofloxacin hydrochloride. And the patent contained the following:

A pharmaceutical tablet comprising over 80% by weight ciprofloxacin hydrochloride monohydrate is disclosed. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to ciprofloxacin hydrochloride monohydrate tablet formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 10, 2001, Kabra, Bhagwati P. published a patent.Category: piperazines The title of the patent was Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum. And the patent contained the following:

Pharmaceutical compositions containing a fluoroquinolone antibiotic drug, xanthan gum and a water-soluble calcium salt in an amount sufficient to make the fluoroquinolone antibiotic drug and xanthan gum compatible are disclosed. A pharmaceutical composition contained ciprofloxacin.HCl 0.35, xanthan gum 0.6, sodium sulfate 1.5, disodium edetate 0.05, BDAB 0.012, NaOH/HCl q.s. pH = 4.5, and water q.s. 100%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to pharmaceutical fluoroquinolone antibiotic drug xanthan gum, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Kuriyama, Masami; Kujirada, Shota; Tsukuda, Kotaro; Onomura, Osamu published an article in 2017, the title of the article was Nickel-Catalyzed Deoxygenative Deuteration of Aryl Sulfamates.Quality Control of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone And the article contains the following content:

The nickel-catalyzed deoxygenative deuteration of aryl/heteroaryl sulfamates was developed, and the effective incorporation of deuterium into a variety of aromatic compounds was achieved with sufficient catalytic efficiency and high deuteration degree. This process tolerated reducible functional moieties and heterocyclic structures. Addnl., a double introduction of deuterium also successfully gave a desired product with a high yield and deuterium content. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Quality Control of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

The Article related to aryl sulfamate deoxygenative deuteration nickel catalyst, General Organic Chemistry: Synthetic Methods and other aspects.Quality Control of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 1987, Lammens, Robert Frank; Mahler, Hans Friedrich; Serno, Peter published a patent.Electric Literature of 86393-32-0 The title of the patent was Infusion solution of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid (ciprofloxacin), especially for antibacterial use. And the patent contained the following:

Aqueous infusion solutions for especially antibacterial use contain ciprofloxacin 0.015-0.5 g/100 mL of a physiol. acceptable acid as stabilizer, with optional adjuvants. An infusion solution contained ciprofloxacin 90, lactic acid (20% g/g) 144.3, HCl 1.5, NaCl 5.4g, and water to 600 mL; its pH was ∼4.3 and osmolarity ∼0.29 osm/kg. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Electric Literature of 86393-32-0

The Article related to antibacterial infusion solution ciprofloxacin acid, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Hashem, F. M.; Sakran, W. S.; Shaker, D. S. published an article in 2003, the title of the article was Ocular bioavailability of ciprofloxacin hydrochloride from certain ophthalmic preparations.Application of 86393-32-0 And the article contains the following content:

The bioavailability of ciprofloxacin hydrochloride (CPX-HCl) in eye tissues and aqueous humor of rabbits was studied. The selected ophthalmic preparations were ophthalmic solution (eye drops) containing hydroxy Pr Me cellulose (HPMC), ophthalmic gels prepared with HPMC or Me cellulose (MC) or sodium alginate. Ocular inserts were prepared from HPMC, or MC or Eudragit RS. The time for peak concentration (tmax) of the drug in the eye tissues and aqueous humor was attained after one hour from the ophthalmic solution, while it was two hours in case of ophthalmic gels irresp. to polymer type. Ocular inserts prepared from HPMC or MC also showed peak concentration time of two hours after application in the rabbit’s eyes. However, the tmax was reached after three hours from Eudragit RS ocular inserts. In all tested ophthalmic formulations. CPX-HCL was available in conjunctiva in a higher concentration than in the cornea, while iris-ciliary body and aqueous humor showed less drug concentration at all time intervals. The corneal drug bioavailability represented by the area under the curve (AUC)0-5 was greatly improved after the application of ocular inserts than other forms (solution or gel). Thus Eudragit RS ocular inserts showed the highest level of the drug bioavailability in eye tissues and aqueous humor due to prolonged retention time, whereas ophthalmic solution was rapidly uptaken and eliminated by tears from eye tissues. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to ciprofloxacin ophthalmic ocular bioavailability, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 1, 2003, Gusler, Gloria; Berner, Bret; Chau, Mei; Padua, Aimee published a patent.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Optimal polymer mixtures for gastric retentive tablets. And the patent contained the following:

Unit dosage form tablets for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of PEG and hydroxypropyl Me cellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the tablet to effect gastric retention and gradual disintegration of the tablet to clear the tablet from the gastrointestinal tract after release of the drug has occurred. Thus, tablets contained gabapentin 60.0,,PEG 24.3, HPMC 14.7, and Mg stearate 1.0%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to polymer mixture gastric retentive tablet, Pharmaceuticals: Formulation and Compounding and other aspects.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 27, 2008, Amirov, N. K.; Egorova, S. N.; Akhmetova, T. A.; Fedorov, A. A.; Galiullina, T. N.; Karipova, R. M.; Stepanova, N. V. published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Composition and method for preparing ciprofloxacin ophthalmic ointment. And the patent contained the following:

The invention proposes an ophthalmic ointment containing ciprofloxacin hydrochloride monohydrate equivalent to the concentration 0.1-0.9% as a free base, a preserving agent, for example nipagin or nipasol, and a sterile base consisting of vaseline melt of sort “”for ophthalmic ointments”” and anhydrous lanolin. The ophthalmic ointment is prepared by melting vaseline and anhydrous lanolin and step-by-step mixing milled ciprofloxacin hydrochloride and the preserving agent with sterile base. The invention provides producing a sterile and stable ciprofloxacin-containing ophthalmic ointment used for local treatment of eye inflammatory diseases and of bacterial etiol. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to eye ointment ciprofloxacin formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics